Emalex Biosciences Acquired by Teva | Healthcare M&A Deal

Teva has acquired Emalex Biosciences, a pharmacy business in Israel, for $700 million in cash plus up to $200 million in milestone payments. Emalex Biosciences develops Ecopipam, a Tourette syndrome treatment for pediatric patients, with orphan drug and fast-track status from the FDA. Teva acquisitions focus on expanding its late-stage innovative pipeline and neuroscience portfolio through a strategic acquisition. The healthcare M&A is a merger acquisition announced for completion in Q3 2026, financed from Teva cash reserves, with net sales-based royalties tied to performance.